Skip to main
PFE

Pfizer (PFE) Stock Forecast & Price Target

Pfizer (PFE) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 8%
Hold 50%
Sell 8%
Strong Sell 0%

Bulls say

Pfizer is well-positioned for growth with a diverse product portfolio and a strong presence in international markets. Positive catalysts, such as upcoming key trials and a potential new standard of care in prostate cancer, could drive sales and expand market share. However, sustainability issues, such as inconsistent integration and potential negative impacts from cost-cutting measures, could hinder long-term growth and credibility. Risks to the rating and price target include challenges to key patents and negative pipeline trial results. Additionally, diversity at the C-suite level remains a concern, though recent initiatives may improve representation.

Bears say

Pfizer is facing significant challenges in terms of its growth potential due to upcoming patent expirations and a slow pipeline of new drugs in development. The company's recent M&A deals have been mixed and there are concerns about its ability to maintain its dividend payout ratio and fund future M&A opportunities. In addition, the company's obesity candidate drugs appear to be lagging behind competitors and it has faced recent setbacks in patent disputes, adding to the risk surrounding the stock.

Pfizer (PFE) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 8% recommend Buy, 50% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pfizer (PFE) Forecast

Analysts have given Pfizer (PFE) a Buy based on their latest research and market trends.

According to 12 analysts, Pfizer (PFE) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pfizer (PFE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.